4 recruiting, 1 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 4, Completed 1 |
Follow Induction Therapy: new trials by email Literature Review of Induction Therapy trials Research Report on Induction Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy QL1706 (bispecific antibody targeting PD-1 and CLTA-4) - Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy | Phase 2 | Recruiting | Shanghai Chest Hospital | 28 | 2025-10-23 | 2026-06-11 |
| Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen - Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2025-07-30 | 2025-07-25 |
| Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC Two-cycle induction chemotherapy + immunotherapy, Three-cycle induction chemotherapy + immunotherapy - Nasopharyngeal Neoplasms, PD-1 Inhibitor | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 208 | 2025-02-25 | 2025-07-01 |
| Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery - Esophageal Cancer, Immunotherapy | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2024-05-01 | 2025-05-30 |
| An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients. Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab) - Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection | Phase 2 | Completed | Genzyme, a Sanofi Company | 240 | 2000-05-01 | 2015-03-18 |
Esophageal Neoplasms (1) · Nasopharyngeal Neoplasms (1) · Pathologic Complete Response (1) · Small Cell Lung Carcinoma (1)
Neoplasms (3) · Neoplasms by Site (3) · Head and Neck Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Disease Progression (1) · Esophageal Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Nasopharyngeal Diseases (1)
Antilymphocyte Serum (1) · Basiliximab (1) · Immunotherapy (1) · thymoglobulin (1)
The First Affiliated Hospital of Xiamen University (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Genzyme, a Sanofi Company (1) · Shanghai Chest Hospital (1)
China (4) · France (1) · Germany (1) · Spain (1) · United Kingdom (1) · United States (1)
Xin Wang (1)